Neurosense Therapeutics Ltd (NRSN)

$2.09 +0.18 (9.42%)
Market Cap 26.10M
Revenue (ttm) 0.00
Net Income (ttm) -10.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 496,000
Avg Vol 317,230
Day's Range N/A - N/A
Shares Out 13.67M
Stochastic %K 56%
Beta 1.66
Analysts Sell
Price Target $10.75

Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 9 799 6183
Address:
Building B, 11 HaMenofim Street, Herzliya, Israel
donkeydink
donkeydink Jul. 7 at 10:47 PM
$NRSN I’m back. Something is about to happen here…I can feel it in my dink. Cmon Alon you little twerp.
0 · Reply
jags2255
jags2255 Jul. 7 at 9:02 PM
$NRSN Bidding it up AH ! Let’s move this puppy !
0 · Reply
Zofar
Zofar Jul. 7 at 8:33 PM
$NRSN fuck himmmm!!! he is torturing ussss!!!
0 · Reply
JK_Capital
JK_Capital Jul. 7 at 8:08 PM
$NRSN got a feeling this one’s gonna blow soon. CEO has been posting a lot on LinkedIn Perhaps we are near the finalization of the partnership?
1 · Reply
funnymoney90210
funnymoney90210 Jul. 7 at 7:56 PM
$NRSN Someone is going to dump with 2 mins to go and I'm ready to buy those shares....let's goooooooo!
0 · Reply
funnymoney90210
funnymoney90210 Jul. 7 at 6:59 PM
$NRSN Keep on buying, buying, buying....we know what is about to happen. Come on $53/share
0 · Reply
Kjac
Kjac Jul. 7 at 4:57 PM
$NRSN are earnings tomorrow?
1 · Reply
supernoob
supernoob Jul. 7 at 4:44 PM
$NRSN some big sell orders couple 10k block up to 2.30
1 · Reply
Johnmarlie
Johnmarlie Jul. 7 at 4:06 PM
$NRSN Hopefully a multi day runner like a while back
0 · Reply
Crocker48
Crocker48 Jul. 7 at 4:06 PM
$NRSN hopefully stays up here
0 · Reply
Latest News on NRSN
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

May 12, 2025, 3:08 PM EDT - 2 months ago

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

May 7, 2025, 8:45 AM EDT - 2 months ago

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

Apr 24, 2025, 9:09 AM EDT - 2 months ago

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

Apr 9, 2025, 8:30 AM EDT - 3 months ago

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

Apr 7, 2025, 5:14 PM EDT - 3 months ago

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Apr 4, 2025, 9:10 AM EDT - 3 months ago

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

Mar 17, 2025, 8:30 AM EDT - 4 months ago

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

Jan 6, 2025, 9:00 AM EST - 6 months ago

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

Dec 23, 2024, 9:00 AM EST - 7 months ago

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

Dec 18, 2024, 10:25 AM EST - 7 months ago

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

Dec 11, 2024, 9:25 AM EST - 7 months ago

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

Dec 4, 2024, 8:30 AM EST - 7 months ago

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

Dec 2, 2024, 8:30 AM EST - 7 months ago

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

Nov 21, 2024, 9:20 AM EST - 8 months ago

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

Oct 28, 2024, 8:30 AM EDT - 9 months ago

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

Oct 24, 2024, 8:30 AM EDT - 9 months ago

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

Oct 15, 2024, 9:15 AM EDT - 9 months ago

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

Oct 9, 2024, 9:00 AM EDT - 9 months ago

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

Oct 7, 2024, 9:00 AM EDT - 9 months ago

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

Sep 24, 2024, 9:05 AM EDT - 10 months ago

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

Sep 24, 2024, 9:00 AM EDT - 10 months ago

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Aug 30, 2024, 4:30 PM EDT - 11 months ago

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

Aug 7, 2024, 2:00 PM EDT - 11 months ago

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

Aug 1, 2024, 9:15 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

Jul 9, 2024, 9:27 AM EDT - 1 year ago

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

This cheap biotech offers investors a play on ALS if trial data continues to impress

Jul 2, 2024, 12:34 PM EDT - 1 year ago

This cheap biotech offers investors a play on ALS if trial data continues to impress

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

Jul 1, 2024, 8:00 AM EDT - 1 year ago

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

Jun 24, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

Jun 21, 2024, 4:30 PM EDT - 1 year ago

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

May 20, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

May 14, 2024, 9:05 AM EDT - 1 year ago

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

May 7, 2024, 8:45 AM EDT - 1 year ago

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

NeuroSense Announces First Quarter 2024 Business Update

May 2, 2024, 9:19 AM EDT - 1 year ago

NeuroSense Announces First Quarter 2024 Business Update

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

Apr 22, 2024, 8:30 AM EDT - 1 year ago

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

Apr 18, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

Apr 12, 2024, 8:30 AM EDT - 1 year ago

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

Apr 10, 2024, 7:16 PM EDT - 1 year ago

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

Apr 9, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

Apr 5, 2024, 9:29 AM EDT - 1 year ago

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

Feb 21, 2024, 8:30 AM EST - 1 year ago

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024

Jan 30, 2024, 8:30 AM EST - 1 year ago

NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024

BIIB

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

Jan 9, 2024, 8:45 AM EST - 1 year ago

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Dec 27, 2023, 5:00 PM EST - 1 year ago

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

Dec 14, 2023, 9:24 AM EST - 1 year ago

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

Dec 5, 2023, 8:00 AM EST - 1 year ago

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023

Dec 4, 2023, 4:01 PM EST - 1 year ago

NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023

NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update

Nov 28, 2023, 8:45 AM EST - 1 year ago

NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update

NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness

Nov 13, 2023, 9:20 AM EST - 1 year ago

NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness

NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences

Nov 9, 2023, 9:00 AM EST - 1 year ago

NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences

donkeydink
donkeydink Jul. 7 at 10:47 PM
$NRSN I’m back. Something is about to happen here…I can feel it in my dink. Cmon Alon you little twerp.
0 · Reply
jags2255
jags2255 Jul. 7 at 9:02 PM
$NRSN Bidding it up AH ! Let’s move this puppy !
0 · Reply
Zofar
Zofar Jul. 7 at 8:33 PM
$NRSN fuck himmmm!!! he is torturing ussss!!!
0 · Reply
JK_Capital
JK_Capital Jul. 7 at 8:08 PM
$NRSN got a feeling this one’s gonna blow soon. CEO has been posting a lot on LinkedIn Perhaps we are near the finalization of the partnership?
1 · Reply
funnymoney90210
funnymoney90210 Jul. 7 at 7:56 PM
$NRSN Someone is going to dump with 2 mins to go and I'm ready to buy those shares....let's goooooooo!
0 · Reply
funnymoney90210
funnymoney90210 Jul. 7 at 6:59 PM
$NRSN Keep on buying, buying, buying....we know what is about to happen. Come on $53/share
0 · Reply
Kjac
Kjac Jul. 7 at 4:57 PM
$NRSN are earnings tomorrow?
1 · Reply
supernoob
supernoob Jul. 7 at 4:44 PM
$NRSN some big sell orders couple 10k block up to 2.30
1 · Reply
Johnmarlie
Johnmarlie Jul. 7 at 4:06 PM
$NRSN Hopefully a multi day runner like a while back
0 · Reply
Crocker48
Crocker48 Jul. 7 at 4:06 PM
$NRSN hopefully stays up here
0 · Reply
mmtiddy
mmtiddy Jul. 7 at 3:32 PM
$NRSN Oh wow? Whats happening
0 · Reply
rml360
rml360 Jul. 7 at 3:30 PM
$NRSN not enough volume to get a hard on
0 · Reply
ACstranger
ACstranger Jul. 7 at 3:25 PM
$NRSN I do not trust the ceo...
3 · Reply
funnymoney90210
funnymoney90210 Jul. 7 at 3:21 PM
$NRSN
0 · Reply
Mitxu
Mitxu Jul. 7 at 3:18 PM
$NRSN Alon must be tired from getting fxxked by Zofar 🤣
2 · Reply
jags2255
jags2255 Jul. 7 at 3:17 PM
$NRSN Nice move , let’s keep it going ! Good things ahead for us !
0 · Reply
Stekli27
Stekli27 Jul. 7 at 2:18 PM
$NRSN Funny how we’re all convinced a deal is brewing, CEO traveling across biotech hotspots, dropping hints — yet the stock is still trading like nothing’s happening. I’m not complaining though… just quietly adding while it’s still cheap. 🤫
1 · Reply
funnymoney90210
funnymoney90210 Jul. 7 at 1:50 PM
$NRSN Earnings pushed to Aug 27th confirmed
2 · Reply
Zofar
Zofar Jul. 7 at 1:32 PM
$NRSN fuck you Alon fuck you! you shit head!!! stop this absurd and resign!!! don't take the company with you!!!
1 · Reply
Zoofar
Zoofar Jul. 7 at 1:14 PM
$NRSN well probably not today…even though it was asked for…
0 · Reply
Alexph23
Alexph23 Jul. 7 at 1:09 PM
$NRSN Deal? Are you there!? Hello!!? Are we gonna see you this week? We all want to see your pretty little face 🥇
0 · Reply
Zoofar
Zoofar Jul. 7 at 9:15 AM
$NRSN where is the money?!? make me reach nrsn! come on alon, bring it in!!! go nrsn
1 · Reply